{"id":22828,"date":"2023-02-06T11:08:11","date_gmt":"2023-02-06T10:08:11","guid":{"rendered":"https:\/\/idibell.cat\/?p=22828"},"modified":"2023-02-06T11:08:48","modified_gmt":"2023-02-06T10:08:48","slug":"sobren-noves-vies-de-tractament-en-lambit-dels-limfomes-cutanis-gracies-als-resultats-dun-farmac-basat-en-la-immunoterapia","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2023\/02\/sobren-noves-vies-de-tractament-en-lambit-dels-limfomes-cutanis-gracies-als-resultats-dun-farmac-basat-en-la-immunoterapia\/","title":{"rendered":"S\u2019obren noves vies de tractament en l\u2019\u00e0mbit dels limfomes cutanis gr\u00e0cies als resultats d\u2019un f\u00e0rmac basat en la immunoter\u00e0pia"},"content":{"rendered":"<p>Un estudi cl\u00ednic liderat per investigadors del grup de recerca en tumors hematopo\u00e8tics i limfoides de l\u2019IDIBELL i del Servei de Dermatologia de l\u2019Hospital Universitari de Bellvitge (HUB) confirma que brentuximab vedotin \u00e9s efica\u00e7 i segur per a alguns tipus de limfomes cutanis de c\u00e8l\u00b7lules T (LCCT). Aix\u00f2 representa un avan\u00e7 significatiu per al tractament d\u2019aquests tipus de c\u00e0ncer de baixa recurr\u00e8ncia, tot i que cr\u00f2nics, progressius i debilitants.<\/p>\n<p><strong>\u00a0<\/strong>Els LCCT es coneixen en conjunt com a limfomes no Hodgkin. Comencen com a erupcions a la pell quan els limf\u00f2cits, un tipus de gl\u00f2buls blancs, es tornen cancerosos per un proc\u00e9s que es desconeix encara. El brentuximab \u00e9s un tipus de ter\u00e0pia dirigida amb un component antic\u00f2s que es fixa a la prote\u00efna CD30, la qual es troba a la superf\u00edcie de les c\u00e8l\u00b7lules tumorals, i que aleshores allibera el f\u00e0rmac tot destruint aquestes c\u00e8l\u00b7lules.<\/p>\n<p>Els resultats -extrets de l\u2019estudi de 67 pacients de 21 centres hospitalaris d\u2019arreu de l\u2019Estat i dades del Registre Espanyol de Limfoma Cutani (RELCP)- s\u2019han publicat a l\u2019<em>European Journal of Dermatology and Veneoreology. <\/em>El treball ha estat coordinat per la doctora Cristina Muniesa, investigadora de l\u2019IDIBELL, de l\u2019HUB i Hospital de Viladecans, i ha comptat amb l\u2019impuls de la Fundaci\u00f3n Piel Sana AEDV.<\/p>\n<p>Fins ara, la pr\u00e0ctica cl\u00ednica real amb brentuximab vedotin era molt limitada en els LCCT, per la baixa prevalen\u00e7a d\u2019aquests c\u00e0ncers.<\/p>\n<p>No obstant aix\u00f2, aquest estudi obre vies de recerca de tractaments, aportant noves dades sobre l\u2019efectivitat d\u2019aquesta immunoter\u00e0pia en el tractament de formes avan\u00e7ades de micosi fungoide i trastorns limfoproliferatius CD30+, aix\u00ed com per a la s\u00edndrome de S\u00e9zary i la micosi fungoide fol\u00b7licular.<\/p>\n<p>Les dades de seguiment a 18 mesos de l\u2019inici amb els cicles de tractament mostren que el 67% dels pacients responien al f\u00e0rmac i el 24% havien aconseguit la remissi\u00f3 total de les plaques i els tumors que presentaven a la pell. Segons la publicaci\u00f3, la ter\u00e0pia t\u00e9 bona toler\u00e0ncia en general, tot i que la neuropatia \u00e9s l\u2019efecte advers m\u00e9s freq\u00fcent, afectant el 57% dels pacients.<\/p>\n<p>&nbsp;<\/p>\n<h3>L\u2019IDIBELL i l\u2019Hospital de Bellvitge, referents en limfomes cutanis<\/h3>\n<p><strong>\u00a0<\/strong>El grup d\u2019investigaci\u00f3 en tumors hematopo\u00e8tics i limfoides de l\u2019IDIBELL i l\u2019HUB genera cont\u00ednuament coneixement sobre l\u2019\u00e0mbit dels limfomes cutanis. En els darrers mesos, la Dra. Cristina Muniesa i el Dr. Octavi Servitje han publicat a la prestigiosa <em>The Lancet Haematology<\/em> els resultats d\u2019un assaig cl\u00ednic que <a href=\"https:\/\/idibell.cat\/2022\/06\/un-assaig-clinic-ofereix-resultat-positius-per-al-tractament-dels-limfomes-cutanis-mes-habituals-amb-un-medicament-immunosupressor\/\">avalua l\u2019\u00fas del pimecrolim\u00fas t\u00f2pic en la micosi fungoide<\/a>.<\/p>\n<p>A m\u00e9s, a finals d\u2019aquest passat octubre, l\u2019Hospital de Bellvitge ha acollit la LXXXV reuni\u00f3 del Club de Limfomes de la Societat Espanyola d\u2019Anatomia Patol\u00f2gica i el Grup de Limfoma Cutani de l\u2019Acad\u00e8mia Espanyola de Dermatologia i Venereologia, organitzat per la Dra. Fina Climent i el Dr. Octavi Servitje, de l\u2019IDIBELL i l\u2019HUB.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Segons els resultats, el brentuximab vedotin \u00e9s efica\u00e7 i segur per a alguns tipus de limfomes cutanis poc freq\u00fcents, els de c\u00e8l\u00b7lules T (LCCT)<\/p>\n","protected":false},"author":8,"featured_media":22831,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,447,449],"tags":[],"class_list":["post-22828","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-tumors-hematopoetics-i-limfoides"],"publishpress_future_action":{"enabled":false,"date":"2025-01-03 02:15:34","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22828","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=22828"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22828\/revisions"}],"predecessor-version":[{"id":22829,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/22828\/revisions\/22829"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/22831"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=22828"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=22828"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=22828"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}